Hemangiosarcomas

Brown, Nancy O.

doi:10.1016/s0195-5616(85)50058-3

Cited by 18 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3][4] German shepherd dogs, golden retrievers, Labrador retrievers, and schnauzers appear to be predisposed. 5,6 Canine noncutaneous HSA is typically a highly malignant tumor, frequently metastasizing to distant organs such as the liver, lungs, heart, skin, and central nervous system. 7,8 Many patients present with internal bleeding due to tumor rupture or disseminated intravascular coagulation.…”

Section: Introductionmentioning

confidence: 99%

Treatment with DAV for Advanced-Stage Hemangiosarcoma in Dogs

Dervisis

Domı́nguez

Newman

et al. 2011

Journal of the American Animal Hospital Association

View full text Add to dashboard Cite

Hemangiosarcoma (HSA) is an aggressive disease that is fairly common in the dog. The authors evaluated a doxorubicin, dacarbazine, and vincristine (DAV) combination protocol in dogs with nonresectable stage II and stage III HSA. Twenty-four dogs were enrolled in this prospective, phase 2 study. Doxorubicin and dacarbazine were administered on day 1 while vincristine was administered on days 8 and 15. The protocol was repeated every 21 days for a maximum of six cycles or until disease progression. Toxicity and efficacy were assessed by clinical and laboratory evaluation and by questionnaires completed by the owners. Of the 24 included dogs, 19 were evaluable for response. The response rate (including five complete responses and four partial responses) was 47.4%. Median time to tumor progression was 101 days and median overall survival was 125 days.Significant toxicities were noted, including 41 high-grade hematologic and 12 high-grade gastrointestinal toxic events.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment with DAV for Advanced-Stage Hemangiosarcoma in Dogs

Dervisis

Domı́nguez

Newman

et al. 2011

Journal of the American Animal Hospital Association

View full text Add to dashboard Cite

show abstract

“…Haemangiosarcoma (HSA) is a malignant neoplasm of vascular endothelial cell origin 1–4 . Canine HSA exhibits aggressive biological behaviour with rapid growth, widespread metastasis and a poor prognosis 1–4 .…”

Section: Introductionmentioning

confidence: 99%

Efficacy of doxorubicin-based chemotherapy for non-resectable canine subcutaneous haemangiosarcoma

Wiley

Rook

Clifford³

et al. 2010

Veterinary and Comparative Oncology

View full text Add to dashboard Cite

Eighteen dogs with measurable subcutaneous haemangiosarcoma (SQHSA) were treated with doxorubicin-based chemotherapy. Response assessment was evaluated and compared using World Health Organization (WHO), Response Evaluation Criteria in Solid Tumours (RECIST) and tumour volume criteria. The overall response rate for all dogs was 38.8% using WHO criteria, 38.8% using RECIST criteria and 44% using tumour volume criteria. One dog had a complete response. The median response duration for all dogs was 53 days (range 13-190 days). Four dogs had complete surgical excision after neoadjuvant chemotherapy. The median progression-free interval for dogs with complete surgical excision after neoadjuvant chemotherapy was significantly longer than those not having surgical excision (207 days versus 83 days, respectively) (P = 0.003). No significant difference in metastasis-free interval or survival time was found between the groups. Doxorubicin-based chemotherapy appears to be effective for non-resectable canine SQHSA, although the response duration is relatively short.

show abstract

“…H emangiosarcoma (HSA) is a malignant tumor of dogs that probably arises from endothelial stem cells and exhibits very aggressive biological behavior. [1][2][3][4] Even with complete surgical excision of the primary tumor, metastasis often occurs early in the postsurgical period and survival times are typically short. For example, the median overall survival time for dogs with stage I or II HSA treated with surgery alone was reported to be 86 days.…”

mentioning

confidence: 99%